Pharmaceutical Market Europe • May 2025 • 3
COMMENT
In our cover story this month, Danny Buckland looks at the struggle to make clinical trials easier to conduct and more attractive to patients while understanding the impact of human behaviour and everyday pressures.
As Danny says: “The energy and intent to create a more welcoming and effective clinical trials climate for patients is there but the obstacles remain significant. Enrolment resistance is still a strain of human behaviour that can remain immune to persuasion while triggering ruinously high drop-out rates.” Read more on page 34.
Also in this issue is an article by Angela Sarmiento Betancourt on Duchenne muscular dystrophy, its impact on patients and why early diagnosis is essential. Angela explains: “Duchenne is a serious condition that affects the muscles, causing them to become weaker and deteriorate over time. In Europe and North America, Duchenne affects six out of every 100,000 individuals.
“Globally, Duchenne is the most prevalent form of muscular dystrophy in children. It primarily affects boys, and it is estimated to occur in approximately one in every 3,500 to 5,000 live male births worldwide, resulting in about 20,000 new cases annually.” Find out more on page 20.
Derek Ansel’s article looks at accelerating innovation and access to rare disease treatments by advancing research through global collaborations and unified clinical trials. As he says: “Although individually rare, rare diseases are not rare when viewed collectively. Globally, approximately 300 million people live with a rare disease and many of them share common needs and experiences.
“Now, more than ever, there is a growing acknowledgment that solving rare disease challenges to expedite patients’ access to life-changing therapies requires regulatory, community and global stakeholder cooperation.” Turn to page 18 to find out more.
Our next issue, in June 2025, will look at assessing HCP engagement priorities and their clinical impact. If you would like to make your voice heard on this topic, please get in touch at sales@pmlive.com
I hope you enjoy this issue!
Iona Everson
Group Managing Editor
Keep up to date with the latest developments in the UK and global healthcare marketplace – sign up to daily or weekly news alerts and fortnightly or monthly bulletins on specific topics at www.pmlive.com/register
THE TEAM
Editorial:
Group Managing Editor
Iona Everson
Deputy Editor
Emily Kimber
Studio:
Executive Director
Karl Equi
Sales:
Business Director
Tara Lovegrove
EDITORIAL ADVISORY BOARD
Philip Atkinson
Founder of Hive-Logic, Lifescience Transformation
Uday Bose
Corporate vice president, head of global marketing oncology, Boehringer Ingelheim
Dr Luc Hermans
VP commercial planning and operations Europe, Asia, Middle East, Gilead Sciences
Stefan Janssens
President EMEA, Cegedim Dendrite
John Morris
Partner, KPMG
Paul Pay
Chief business development officer, Norgine
Mark Rothera
Chief executive officer, Orchard Therapeutics
Ian Talmage
Senior vice president, global marketing, general medicine, Bayer Pharmaceuticals
PUBLISHED BY
PMGroup Worldwide Ltd
44 Maiden Lane
Covent Garden
London
WC2E 7LN
CONTACT US
General enquiries: info@pmlive.com
Editorial: editor@pmlive.com
Advertising: sales@pmlive.com
Subscriptions: subscriptions@pmlive.com
Views expressed by the contributors do not necessarily represent those of the publisher, editor or staff.
© 2025 PMGroup
All rights reserved. No part of this publication may be copied, reproduced, transmitted, photocopied, recorded or stored on any retrieval system without the prior written consent of the publishers.
The magazine is also available at the following subscription rates: £120 UK, £180 Europe, £210 RoW